Doctors, clinics, and medical practices buy MUSE stem cells wholesale, direct from CellGenic. MUSE cells are a naturally occurring, SSEA-3 positive subpopulation of mesenchymal stem cells, first described in 2010 by Kuroda and colleagues at Tohoku University. They make up roughly 0.01 to 0.03% of bone marrow mononucleated cells and 1 to 6% of cultured mesenchymal populations, with the exact fraction shifting by tissue source and handling. CellGenic supplies MUSE-enriched cellular research material, isolated from umbilical cord Wharton’s Jelly, to verified physicians, clinic owners, and researchers for laboratory research and preclinical use only.
Five vials make up the 100 million cell minimum order.
Every format ships to the same release standard: minimum 90% SSEA-3 positivity, a Certificate of Analysis by batch number, and cold-chain delivery in the vapor phase of liquid nitrogen.
A full breakdown of MUSE cell biology, including marker profiles and culture behaviour, is covered in CellGenic’s clinician’s guide.
Every MUSE cell is a mesenchymal stem cell, but the reverse is not true. MUSE cells are a small, marker-defined fraction within a much larger and more heterogeneous mesenchymal population. The distinction matters for research design because a standard MSC preparation and a MUSE-enriched preparation are not interchangeable inputs.
Three properties are worth distinguishing when comparing research material. Differentiation lineage span is reported as broader for MUSE cells than for unselected MSCs. Injury-site homing behaviour, discussed further below, is reported as active for MUSE cells via a specific receptor pathway, where standard MSC populations are more often described as passive. And documented tumour marker profiles differ: published safety data on MUSE cells has not reported the c-Myc expression associated with pluripotent stem cell lines, a distinction worth verifying against a supplier’s own release documentation rather than assuming it applies to any product labelled “MSC.”
CellGenic’s comparison article sets out the full distinction, including how marker documentation should be requested from any supplier.
Published preclinical research reports several safety-relevant characteristics of MUSE cells. These figures describe scientific literature on MUSE cell biology generally. They are not performance claims for CellGenic’s own research material and do not describe its use in humans or animals by CellGenic or its providers.
Across the studied models in the published literature, MUSE cells have not been reported to form teratomas or other tumours, a contrast with pluripotent stem cell lines such as iPSCs and embryonic stem cells, which carry a documented tumour risk tied to markers including c-Myc, OCT4, SOX2, and NANOG.
MUSE cells are reported to express low levels of HLA class I and II surface antigens. Published studies describe allogeneic administration in animal models without immunosuppressant medication and without observed rejection events, a variable that is directly relevant to how research protocols involving allogeneic material are designed.
As noted above, MUSE cells are documented to survive hostile culture conditions, including serumfree, hypoxic, and enzymatically harsh environments, at rates substantially higher than unselected MSC populations exposed to the same conditions.
A fully cited breakdown of tumorigenicity, immunogenicity, and stress tolerance data sits in CellGenic’s
dedicated safety article.
MUSE cells occur naturally within connective tissue. CellGenic sources its MUSE-enriched research material from umbilical cord Wharton’s Jelly, then applies a precision isolation protocol targeted at the SSEA-3-positive fraction, rather than optimizing for total mesenchymal cell count alone.
Every lot of CellGenic MUSE Cells is manufactured to a minimum 90% SSEA-3 positivity threshold, confirmed by quality control testing before release. Identity, sterility, and potency testing, along with mycoplasma screening, are documented on every lot, and a Certificate of Analysis is available by batch number. Manufacturing takes place in a cGMP facility holding ISO 20387 and ISO 7 cleanroom certification.
A complete walkthrough of the isolation protocol, including how umbilical cord sourcing compares with other tissue origins, is available in CellGenic’s sourcing article.
There is currently no approved MUSE cell therapy. Human studies published to date are early phase, conducted by independent third-party research groups using their own MUSE cell products, and are not connected to CellGenic or any product CellGenic supplies.
Two gaps are worth stating plainly rather than glossing over. No published trial has evaluated MUSE cells in cerebral palsy, and no registered trial exists for autism, despite both terms appearing in general search interest around MUSE cell topics. The nearest published paediatric evidence is in neonatal hypoxic-ischaemic encephalopathy, a distinct condition, and presenting that evidence as support for cerebral palsy would overstate what has actually been studied.
The full state of published trials, including phase, indication, and what remains unstudied, is set out in CellGenic’s clinical trials article.
MUSE cells express the S1PR2 receptor, which responds to sphingosine-1-phosphate released by stressed or damaged tissue. Published research associates this receptor with directed migration toward injury-signal gradients in animal-model systems, following intravenous administration rather than requiring direct injection at the target site.
The clearest published example is a mouse hindlimb ischaemia study, which reported recovered blood flow, increased microvascular density, and reduced fibrosis following MUSE cell administration (Hori et al., 2022, PMID 36440014). No published study has demonstrated regeneration of a limb or any comparable structure in any species, and that claim should not be inferred from this or any homing mechanism research. The complete mechanism, including the receptor biology and every model system studied to date, is covered in CellGenic’s homing mechanism article.
MUSE cells were first described in 2010 by a research group led by Mari Dezawa at Tohoku University, working with bone marrow and skin fibroblast populations. The name reflects the two properties the group used to identify the cells: their capacity for multilineage differentiation and their tolerance of severe cellular stress.
CellGenic is not affiliated with, licensed by, or endorsed by Dezawa’s laboratory or any institution named in the original research, and does not supply any trademarked product associated with that group. CellGenic’s MUSE Cells research material is isolated and manufactured independently, using CellGenic’s own protocol and release specification.
A fuller account of the discovery and its early research history is in CellGenic’s discovery article.
Four properties, each covered in more depth above, are the reasons MUSE-enriched material comes up in research protocol design more often than an unselected MSC population.
There is currently no approved MUSE cell therapy, and CellGenic’s MUSE Cells research material is supplied strictly for laboratory research and preclinical use. It is not a drug, food, or cosmetic, and bodily introduction into humans or animals is not permitted under its intended use.
A physician or clinic considering any use of cellular research material outside a laboratory research setting carries sole responsibility for independently verifying their own regulatory, licensing, and professional obligations before doing so. CellGenic does not provide legal or regulatory advice and makes no representation about the permissibility of any use in any jurisdiction.
What a physician should establish before evaluating any cellular research material supplier is covered in CellGenic’s diligence article.
No. There is currently no approved MUSE cell therapy. CellGenic’s MUSE Cells research material is supplied for laboratory research and preclinical use only.
Every lot is manufactured to a minimum 90% SSEA-3 positivity threshold, confirmed by quality control testing. Identity, sterility, and potency testing, along with mycoplasma screening, are documented on every lot, with a Certificate of Analysis available by batch number.
MUSE cells are a small, SSEA-3 positive fraction within the broader mesenchymal stem cell population. Published research reports a broader differentiation span and active injury-site homing behaviour for this fraction compared with unselected MSC populations.
CellGenic sells exclusively to verified licensed physicians, clinic owners, and researchers who complete provider verification. Pricing, live availability, and Certificates of Analysis unlock once your account is approved.
Apply for provider access to unlock pricing, live availability, and Certificates of Analysis across CellGenic’s cellular, exosome, hormone, and peptide research material.